Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Introduction to the Review Series. Chronic myeloid leukemia in 2026.

Haematologica·2026

Same author

Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.

The New England journal of medicine·2026

Same author

Portrait of a Pioneer: Fred Appelbaum.

Transplantation and cellular therapy·2026

Same author

Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

The New England journal of medicine·2026

Same author

Shared Identity and Patient Care: Adherence to Guideline-Recommended Biomarker Testing in Chronic Myeloid Leukemia.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Donor-derived del[20q] following allogeneic-hematopoietic cell transplantation: a case with 26-year follow-up and literature review.

Bone marrow transplantation·2026

Search research articles

Related Experiment Video

Updated: Mar 16, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

When to Consider Allogeneic Transplantation in CML.

Jerald Radich¹

¹Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA.

Clinical Lymphoma, Myeloma & Leukemia

|August 14, 2016

Summary

Tyrosine kinase inhibitor (TKI) therapy has transformed chronic myeloid leukemia (CML) treatment. Allogeneic transplantation is now reserved for TKI intolerance, resistance, or advanced CML phases.

Keywords:

Bone marrow transplantation Chronic myeloid leukemia Tyrosine kinase inhibitors

More Related Videos

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Related Experiment Videos

Last Updated: Mar 16, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Chronic myeloid leukemia (CML) treatment has evolved significantly.
Tyrosine kinase inhibitors (TKIs) represent a major advancement in CML therapy.

Purpose of the Study:

To review the current role of allogeneic transplantation in the context of TKI therapy for CML.
To delineate the specific scenarios where allogeneic transplantation remains a crucial therapeutic option.

Main Methods:

Literature review of CML treatment strategies.
Analysis of clinical guidelines and outcomes data.
Comparative assessment of TKI therapy versus allogeneic transplantation.

Main Results:

TKI therapy is the primary treatment modality for most CML patients.
Allogeneic transplantation is indicated for patients with TKI resistance or intolerance.
Transplantation is also considered for CML progression to accelerated or blast phases.

Conclusions:

Allogeneic transplantation is a vital, albeit secondary, treatment option for specific CML patient populations.
The strategic application of TKIs has redefined the indications for stem cell transplantation in CML.